Compare BEN & COO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEN | COO |
|---|---|---|
| Founded | 1947 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 15.5B |
| IPO Year | N/A | N/A |
| Metric | BEN | COO |
|---|---|---|
| Price | $23.40 | $81.98 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $23.05 | ★ $85.82 |
| AVG Volume (30 Days) | ★ 4.3M | 3.3M |
| Earning Date | 11-07-2025 | 12-04-2025 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | ★ 7.28 | N/A |
| EPS | 0.91 | ★ 1.87 |
| Revenue | ★ $8,770,700,000.00 | $4,092,400,000.00 |
| Revenue This Year | N/A | $6.66 |
| Revenue Next Year | $5.60 | $5.54 |
| P/E Ratio | ★ $25.71 | $43.53 |
| Revenue Growth | 3.45 | ★ 5.06 |
| 52 Week Low | $16.25 | $61.78 |
| 52 Week High | $26.08 | $104.47 |
| Indicator | BEN | COO |
|---|---|---|
| Relative Strength Index (RSI) | 60.98 | 72.89 |
| Support Level | $22.34 | $75.25 |
| Resistance Level | $23.54 | $78.69 |
| Average True Range (ATR) | 0.46 | 2.48 |
| MACD | 0.19 | 0.47 |
| Stochastic Oscillator | 94.44 | 55.39 |
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.